r&d-header.jpg

Development of New Antiviral Drug

New Antiviral Drug

Currently, several antiviral, such as synthetic drugs and interferon, are available on the market which still have many limitations in their clinical applications. The continued use of chemical drugs can lead to increased resistance and although interferon shows a broad spectrum of antiviral activity in dealing with the range of viruses, its activity is not as effective as people had expected. Developed countries like the USA have started realizing the potential of composite materials possessing promising results.

A number of possibilities have been discussed in various research papers, which are a good start, but the methods to obtain such substances are yet in the early elementary stage. So far, methods for its purification have not been standardized. We have conducted extensive research for decades and have developed techniques to obtain the proprietary source material (VSF: Virus Suppressing Factor). The company received a USA Patent in April 2010 and is ready to submit a patent regarding an appropriated human VSF worldwide.

What is VSF?

According to reports, the expected market size of antiviral agents is about 30 billion USD. Since a significant portion of all incurable diseases are viral diseases, the antiviral market has a tremendous growth potential.

VSF is produced in the body, similar to that of interferon; however it shows much greater antiviral activity over a wider range of viruses in animal experiments than interferon. Therefore, if developed as an antiviral therapeutic, VSF can overcome many of the limitations of the existing synthetic antiviral as well as interferon.
business-sub